No abstract

AIT is indicated for the treatment of moderate-to-severe intermittent or persistent symptoms of allergic rhinitis. AIT can be administered to those >5 years of age and has been shown to be safe in children as young as 3 years of age. In this article, AIT and other types of immunotherapies were discussed as well as the indications for immunotherapy.

Hereditary sensorineural hearing loss is a preventive disease. A random sample survey of 6,421 Saudi infants and children was conducted to study the prevalence of consanguineous marriage and its effect on the prevalence of hereditary sensorineural hearing loss. First cousin consanguineous marriage was found among the parents of 21.1% of the children studied and second cousin consanguinity was present in 23%. The overall prevalence of hereditary sensorineural hearing loss was 1.7%. A higher prevalence of 2.8% of mis type of deafness was found among children of first cousin parents, compared with 1.6% among children of more distant consanguinity and 1.4% among non-consanguineous families' children. The study showed that consanguinity is widely practiced among the population surveyed and demonstrated a marked adverse effect on the incidence of hereditary sensorineural hearing impairment. Ann Saudi Med 1993;13(5):447-450.

Intranasal corticosteroids have been used in adenoidal hypertrophy and adenotonsillar hypertrophy patients, decreasing rates of surgery for adenotonsillar hypertrophy.

Patients treated with SCIT are at risk of both local and systemic adverse reactions; however, in most cases, symptoms are readily reversible if they are recognized early and treated promptly. The safety profile of SLIT is good; therefore, SLIT can be self-administered by patients in their homes. In this article, we reviewed the efficacy and safety of allergen immunotherapy.

No abstract

No abstract

We assessed the use of antileukotrienes for treating adenotonsillar hypertrophy. We reviewed the current literature on the anatomy of adenotonsillar tissue, adenotonsillar hypertrophy/hyperplasia (and the associated pathophysiology and symptoms), and the effects of antileukotrienes used to treat adenotonsillar hypertrophy. Leukotrienes (LTs) are inflammatory mediators produced by a number of cell types, including mast cells, eosinophils, basophils, macrophages, and monocytes. There are several types (e.g., LTA4, LTB4, LTC4, LTD4, and LTE4). By competitive binding to the cysLT1 receptor, LT-receptor antagonist drugs such as montelukast, zafirlukast, and pranlukast block the effects of cySHLTs, improving the symptoms of some chronic respiratory diseases. High numbers of LT receptors have been found in the tonsils of children with obstructive sleep apnea. Antileukotrienes reduce the apnea-hypopnea index and adenotonsillar inflammation. Antileukotrienes may be useful for children with adenotonsillar hypertrophy due to their anti-inflammatory effects, which help to reduce adenotonsillar inflammation.